Financials

  • Market Capitalization 124.13 M
  • Employee 29
  • Founded 1998
  • CEO N/A
  • Website www.oncolyticsbiotech.com
  • Headquarter Nevada, United States
  • FIGI BBG000DVS826
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-2.91
Índice preço/fluxo de caixa
-169.59

Oncolytics Biotech Inc. - Common Stock

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

Notícias